GlassScriptPhysician profile
Rudy Bohinc
NPI 1558310995
$8,226.45
in general payments reported to CMS, 2019-2025
46 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $717 · 2021: $1,373 · 2022: $1,350 · 2023: $1,572 · 2024: $1,518 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,892.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.29 | 2021-2025 | Linzess, Vraylar, Viberzi |
| Astrazeneca Pharmaceuticals LP | $889.54 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $814.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $752.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $596.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $444.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $434.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $347.55 | 2019-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.70 | 2019-2025 | Jardiance |
| Abbott Laboratories | $252.55 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $210.88 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.05 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $127.42 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $125.02 | 2019-2023 | Steglatro, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $120.43 | 2022-2025 | Eliquis, Camzyos |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudy Bohinc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.